Ensartinib standard usage, dosage and usage cycle

Ensartinib is a new generation ALK (anaplastic lymphoma kinase) inhibitor specifically used to treat patients with ALK-positive non-small cell lung cancer (NSCLC). The drug was jointly developed by China's Betta Pharmaceuticals and the American company Xcovery, and its trade name is "Ensartinib Tablets". It has strong target selectivity and has a good inhibitory effect on drug-resistant variants of ALK mutations. It especially shows unique advantages in overcoming resistance to crizotinib. Since being approved for marketing by the China National Food and Drug Administration (NMPA) in 2021, ensartinib has gradually become the first-line treatment option for ALKpositive NSCLC patients.

1. Standard recommended dosage

According to Chinese drug instructions and international clinical trial data, the standard recommended dose of ensartinib is:

225mg (mg), taken orally once daily.

Patients need to swallow the tablet whole and should not break it or chew it. It is recommended to take it on an empty stomach, that is, no food is allowed within 1 hour before taking the medicine or 2 hours after taking the medicine.

Ensartinib is administered at a fixed dose and does not adjust the dose based on body weight. However, if serious adverse reactions occur (such as grade 2 or above rash, elevated liver enzymes, etc.), the dose must be gradually reduced or temporarily discontinued according to the doctor's advice, as follows:

First dose adjustment: from 225mg to 200mg;

Second dose adjustment: If 200mg is not tolerated, further reduce to 175mg;

If it is not tolerated at the lowest dose, the drug needs to be discontinued.

Dosage adjustment recommendations should be made under the strict guidance of a doctor, and patients should not change the dose or frequency on their own.

2. Medication cycle and treatment course instructions

Ensartinib is a long-term maintenance treatment, which means patients need to take the drug continuously every day until disease progression or intolerable toxicity occurs. This means that the treatment cycle is not a fixed course, but is taken continuously based on efficacy and safety.

In the I/II phase studies and the eXalt3 study, the median time for most patients to receive treatment was 11-13 months, and some patients with good responses could take the drug for more than two years. In the initial stage (within 1-3 months), close follow-up should be conducted, including imaging evaluation, liver and kidney function and ECG monitoring, to determine efficacy and tolerability.

Clinical recommendations are as follows:

First three months: Monthly follow-up visit 1 time, review of imaging (CT or MRI), blood routine and liver function;

After three months: If the condition is stable, the follow-up interval can be extended to every 2-3 months1 times;

When disease progression or adverse reactions are found to worsen: Should immediately evaluate whether to discontinue the drug, change the drug, or perform combined therapy.

Ensartinib has the characteristic of rapid onset of action, and some patients can experience tumor shrinkage within 4 weeks, so initial evaluation is particularly critical.

3. Medication guidance for special populations

Patients with abnormal liver and kidney function:

Ensartinib is mainly metabolized in the liver and should be used with caution in patients with moderate to severe hepatic impairment. Dosage adjustments are usually not required in patients with mild liver dysfunction, but weekly monitoring of liver enzyme levels is recommended. No dose adjustment has been found to be necessary in patients with renal insufficiency.

1.Used by the elderly:

Although clinical studies have not shown that age has a significant impact on pharmacokinetics, elderly patients may have multiple underlying diseases and must pay special attention to drug interactions and tolerance during medication.

2.Children and pregnant women:

Ensartinib has not yet established safety and effectiveness data in people under the age of 18. Its use during pregnancy has potential fetal toxicity and strict contraception should be used.

4. Combination therapy and drug resistance issues

Ensartinib is usually used orally as a single agent, but when resistance mutations (such asG1202R) occur or brain metastases progress, some patients may need to be combined with other treatment strategies, such as:

Combination immunotherapy or chemotherapy;

Replace with third-generationALK inhibitors (such as lorlatinib);

Patients with brain metastases should consider stereotactic radiotherapy or intracranial dressing change depending on the situation.

Studies have shown that ensartinib has strong penetration into brain metastases and is one of the preferred alternatives for crizotinib resistance or brain metastases.

As a first-line treatment for ALK positive non-small cell lung cancer, ensartinib is recommended to be taken orally at a fixed dose of 225mg per day and continued until the disease progresses or is intolerable. Its treatment cycle is usually long-term maintenance, with stable efficacy and high brain metastasis control rate, making it an important choice after crizotinib. Patients should use it scientifically and standardizedly under the guidance of a doctor, and regularly review imaging and blood indicators. If adverse reactions are found, the dosage or treatment should be adjusted in a timely manner.

In addition, since ensartinib is an oral targeted drug, patients need to have good awareness of compliance and resistance monitoring. Reasonable arrangement of medication time, avoidance of missed doses, and regular follow-up are important guarantees to ensure the therapeutic effect. In the future, with the accumulation of more real-world data, the role of ensartinib in different mutation types and combination therapy will be further clarified, and it will also bring longer-lasting survival benefits to patients with ALK-positive lung cancer.

Reference materials:https://www.drugs.com/